Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of ESSA Pharma Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased ESSA Pharma securities between December 12, 2023, and October 31, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5]. - The deadline to move the Court to serve as lead plaintiff is March 25, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3]. Group 3: Case Allegations - The lawsuit alleges that ESSA Pharma failed to disclose critical information regarding the efficacy of masofaniten in combination with enzalutamide, leading to misleading public statements [4]. - Specific claims include that the combination treatment had no clear efficacy benefit over enzalutamide alone and was less effective in treating prostate cancer than previously stated [4]. - The lawsuit asserts that the M-E Combination Study was unlikely to meet its primary endpoint, resulting in overstated clinical and commercial prospects for masofaniten [4].

Core Viewpoint - A class action has been filed against ESSA Pharma Inc. for allegedly misleading investors about the efficacy of its drug candidate masofaniten, particularly in its combination with enzalutamide for treating prostate cancer [1][2]. Company Overview - ESSA Pharma Inc. is a clinical stage pharmaceutical company focused on developing small molecule drugs for prostate cancer treatment [1]. - The lead product candidate is masofaniten, which was being tested in combination with enzalutamide in a clinical trial for metastatic castration-resistant prostate cancer (CRPC) [1]. Allegations - The complaint alleges that ESSA failed to disclose that: - Masofaniten combined with enzalutamide showed no clear efficacy benefit over enzalutamide alone [2]. - The combination was less effective in treating prostate cancer than previously indicated [2]. - The M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint [2]. - The company overstated masofaniten's clinical, regulatory, and commercial prospects [2]. Recent Developments - On October 31, 2024, ESSA announced the termination of Phase 2 of the M-E Combination Study, citing an interim review that indicated a higher rate of PSA90 response in patients treated with enzalutamide alone compared to the combination [3]. - The company noted that a futility analysis showed a low likelihood of meeting the study's primary endpoint and planned to terminate other clinical studies involving masofaniten [3]. - Following this announcement, ESSA's stock price dropped by $3.80 per share, or 73.08%, closing at $1.40 per share on November 1, 2024 [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from December 12, 2023, to October 31, 2024 [2]. - Allegations include that the defendants made materially false statements about masofaniten's efficacy, claiming it had benefits over enzalutamide alone, which was not supported by evidence [2]. - The M-E Combination Study was unlikely to meet its primary endpoint, contradicting the defendants' claims about masofaniten's prospects [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by March 25, 2025, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4]. - The firm seeks recovery for investors who suffered losses due to misleading statements that inflated stock prices [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][2]. Group 1: Allegations - The complaint alleges that during the class period from December 12, 2023, to October 31, 2024, the defendants made materially false and misleading statements about masofaniten's efficacy [2]. - It is claimed that masofaniten in combination with enzalutamide did not demonstrate a clear efficacy benefit over enzalutamide alone, contrary to what was communicated to investors [2]. - The M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint, indicating that the clinical and commercial prospects of masofaniten were overstated [2]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is March 25, 2025, and they are encouraged to register without delay [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [3]. - There is no cost or obligation for shareholders to participate in this class action [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and fraud [4]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from December 12, 2023, to October 31, 2024 [3]. - Allegations include that the defendants made materially false and misleading statements about masofaniten's efficacy, claiming it had no clear benefit over enzalutamide alone [3]. - It is asserted that the M-E Combination Study was unlikely to meet its primary endpoint, leading to overstated clinical and commercial prospects for masofaniten [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by March 25, 2025, to potentially become lead plaintiffs [4]. - Registration will provide shareholders with updates throughout the case lifecycle, and participation incurs no cost or obligation [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights against deceit and fraud, emphasizing responsible business practices [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][2]. Group 1: Allegations - The complaint alleges that during the class period from December 12, 2023, to October 31, 2024, the defendants made materially false and misleading statements about masofaniten's efficacy [2]. - It is claimed that masofaniten in combination with enzalutamide did not demonstrate a clear efficacy benefit over enzalutamide alone, contrary to what was communicated to investors [2]. - The M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint, indicating that the clinical and commercial prospects of masofaniten were overstated [2]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is March 25, 2025, and they are encouraged to register without delay [3]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's status [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and illegal business practices [4]. - The firm is committed to ensuring companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [4].

Core Viewpoint - A class action securities lawsuit has been filed against ESSA Pharma Inc. due to alleged securities fraud affecting investors between December 12, 2023, and October 31, 2024 [1][2] Group 1: Allegations and Claims - The lawsuit claims that the defendants made false statements regarding the efficacy of masofaniten in combination with enzalutamide, suggesting it had no clear benefit over enzalutamide alone [2] - It is alleged that masofaniten was less effective in treating prostate cancer than previously communicated to investors [2] - The M-E Combination Study was reportedly unlikely to meet its prespecified Phase 2 primary endpoint, contradicting the defendants' claims [2] - Defendants are accused of overstating masofaniten's clinical, regulatory, and commercial prospects, leading to materially false and misleading public statements [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until March 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - A class action has been filed against ESSA Pharma Inc. for allegedly misleading investors about the efficacy of its drug candidate masofaniten, particularly in its combination with enzalutamide for treating prostate cancer [1][2]. Group 1: Allegations and Findings - The complaint alleges that ESSA failed to disclose that masofaniten combined with enzalutamide showed no clear efficacy benefit over enzalutamide alone [2]. - It is claimed that the M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint, indicating that the company overstated masofaniten's clinical and commercial prospects [2]. - On October 31, 2024, ESSA announced the termination of Phase 2 of the M-E Combination Study, citing a higher rate of PSA90 response in patients treated with enzalutamide alone and no clear efficacy benefit from the combination [3]. Group 2: Market Impact - Following the announcement of the study termination, ESSA's stock price fell by $3.80 per share, a decrease of 73.08%, closing at $1.40 per share on November 1, 2024 [3]. Group 3: Class Action Participation - Investors may be eligible to participate in the class action against ESSA Pharma Inc., with options to serve as lead plaintiff or remain an absent class member [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for participation [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ESSA Pharma Inc. regarding a class action lawsuit due to alleged misleading statements related to the efficacy of masofaniten in combination with enzalutamide for prostate cancer treatment [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from December 12, 2023, to October 31, 2024 [2]. - Allegations include that the defendants made materially false and misleading statements about masofaniten's efficacy and overstated its clinical and commercial prospects [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by March 25, 2025, to potentially become lead plaintiffs [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to deceitful practices by companies [4].

Financial Performance - ESSA reported a net loss of $8.5 million for Q1 2025, compared to a net loss of $6.0 million for Q1 2024, representing an increase of approximately 42%[3] - The total operating expenses for Q1 2025 were $9.7 million, compared to $7.6 million for Q1 2024, indicating a year-over-year increase of approximately 28%[12] - The company reported a basic and diluted loss per common share of $0.19 for Q1 2025, compared to $0.14 for Q1 2024[12] Research and Development - Research and Development (R&D) expenditures for Q1 2025 were $5.5 million, slightly up from $5.4 million in Q1 2024, with non-cash share-based payments increasing to $729,780 from $526,241[3] General and Administrative Expenses - General and Administration (G&A) expenditures rose significantly to $4.2 million in Q1 2025 from $2.2 million in Q1 2024, with non-cash share-based payments increasing to $1,972,151 from $277,177[3] Cash and Assets - As of December 31, 2024, ESSA had cash reserves and short-term investments of $120.6 million and net working capital of $118.8 million, with no long-term debt[9] - ESSA's total assets decreased to $122.6 million as of December 31, 2024, down from $128.1 million as of September 30, 2024[11] Strategic Options - The company is exploring strategic options including potential mergers, asset sales, or other business combinations to maximize shareholder value following the termination of clinical trials for masofaniten[2] - The company anticipates headcount and other cost reductions as part of its strategic review process[2] Shareholder Information - The weighted average number of common shares outstanding increased to 44,388,550 in Q1 2025 from 44,129,491 in Q1 2024[12]